SYN-004 (Synermore Biologics)

重组抗EGFR单抗（兴盟生物）

Report date: 2022/08/22 20:00:20

Base Information

Drug NameSYN-004 (Synermore Biologics)
Drug Alias Name重组抗EGFR单克隆抗体（深圳龙瑞药业）LR-004SYN-004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsCarcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLonn Ryonn Pharma LtdSynermore Biologics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSynermore Biologics (Suzhou) Co LtdLonn Ryonn Pharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsCarcinoma
Inactive IndicationsLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A